A A A

Visitenkarte


Prof. Dr. med. Michael Hertl

Direktor der Hautklinik

Tel.: 06421/58-66281
Fax: 06421/58-62902

michael.hertl@med.uni-marburg.de

Originalarbeiten:

  • Haase C., Büdinger L., Borradori L., Yee C., Merk H.F., Yancey K., Hertl M.
    Detection of IgG autoantibodies in the sera of patients with bullous pemphigoid and pemphigoid gestationis: ELISA studies utilizing a baculovirus-encoded form of the extracellular domain of BPAG2.J. Invest. Dermatol. 110:282-286, 1998
  • Büdinger L., Borradori L., Yee C., Eming R., Ferencik S., Grosse-Wilde H., Merk H.F., Yancey K., Hertl M.Identification and characterization of autoreactive T cell responses to bullous pemphigoid (BP) antigen 2 in patients with BP and HLA-DQß1*0301 positive normals.J. Clin. Invest. 102:2082-2089, 1998
  • Büdinger L., Neuser N., Totzke U., Merk H. F., Hertl M.
    Preferential detection of TCR-Vß17+ peripheral and cutaneous T cells in Nickel-induced contact dermatitis. J. Immunol 167:6038-6044, 2001
  • Hofmann S., Thoma-Uszynski S., Stauber A, Schuler G, Borradori L, Hertl M. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the N- and C-terminal regions of the BP180 ectodomain. J. Invest. Dermatol. 119:1065-1073, 2002
  • Lüftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M. Successful removal of pathogenic autoantibodies in pemphigus by immunadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br. J. Dermatol. 149(3):598-605, 2003
  • Veldman C., Stauber A., Uter W., Schuler G., Wassmuth R., Hertl M. Dichotomy of autoreactive T helper 1 and 2 responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles J. Immunol., 170:635-642, 2003
  • Veldman C, Gebhard KL, Uter W, Wassmuth R, Grötzinger J, Schultz E, Hertl M. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals.
    J. Immunol. 172:3883-3892, 2004
  • Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P,
    Treudler R, Zouboulis C, Schuler G, Borradori L, Hertl M. BP230 and BP180 autoantibodies in bullous pemphigoid. J. Invest. Dermatol. 122:1413-1422, 2004
  • Veldman C, Höhne A.., Dieckmann D., Schuler G., Hertl M.
    Type I regulatory T cells specific for desmoglein 3 predominate in healthy individuals compared to patients with pemphigus vulgaris. J. Immunol. 172:6468-6475, 2004
  • Jacobi A, Antoni C, Manger B, Schuler G, Hertl M.
    Long-term efficacy and safety of the tumor necrosis factor alpha inhibitor inflixinab in moderate and severe atopic dermatitis. J. Am. Acad. Dermatol. 52:522-526, 2005
  • Bekou V, Thoma-Uszynski S, Wendler O, Uter W, Schwietzke S, Hunziker T, Zouboulis CC, Schuler G, Sorokin L, Hertl M. Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J. Invest. Dermatol. 124 (4):732-40, 2005
  • Eming R, Rech J, Kalden JR, Schuler G, Harrer T, Hertl M.
    Removal of pathogenic autoantibodies in patients with severe pemphigus by immunoadsorption.
    Dermatology. 2006;212(2):177-87.Veldman C, Pahl A, Beissert S, Dieckmann D, Schuler G, Hertl M. Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type I regulatory T cells into autoaggressive T helper 2-like cells. J Immunol. 2006
  • Mar 1;176(5):3215-22.Thoma-Uszysnki S, Uter W, Schwietzke S, Schuler G, Borradori L, Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize identical regions of BP180 and BP230. J Immunol. 2006 Feb 1;176(3):2015-23
  • Veldmann C, Eming R, Wolff-Franke S, Sonderstrup G, Kwok WW, Hertl M.
    Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DRbeta10402 tetramers. Clin Immunol. 2006;16: in press

Überrsichtsarbeiten:

  • Hertl M., Merk H.F.
    Lymphocyte activation in cutaneous drug reactions.
    J. Invest. Dermatol. 105:95s-98s, 1995
  • Hertl M, Eming R, Veldman C.
    T cell control in autoimmune bullous skin disorders.
    J Clin Invest. 2006 May;116(5):1159-66.
  • Veldman C, Nagel A, Hertl M.
    Type I regulatory T cells in autoimmunity and inflammatory diseases. Int Arch Allergy Immunol. 2006;140(2):174-83.
  • Eming R, Hertl M.
    Autoimmune Diagnostics Working Group. Autoimmune bullous disorders. Clin Chem Lab Med. 2006;44(2):144-9.
  • Eming R, Hertl M.
    Immunoadsorption in pemphigus. Autoimmunity. 2006;39(7):609-16.
  • Jacobi A, Mahler V, Schuler G, Hertl M.
    Treatment of inflammatory dermatoses by tumour nercrosis factor antagonists. J Eur Acad Dermatol Venereol. 2006;20(10):1171-87

Buchbeiträge:

  • Hertl M. (Hrsg.)
    Autoimmune diseases of the skin.
    Springer Verlag, Wien/New York, 2001
  • Hertl M.
    Immunologisch bedingte Hauterkrankungen (Herausgabe der englischen Ausgabe von T. Lawley und K.B. Yancey). Harrison's Textbook of Internal Medicine (15. dt. Auflage). Wissenschaftsverlagsgesellschaft, Berlin (im Druck), 2002
  • Hertl M.
    Blasenbildende Autoimmundermatosen. In W. Sterry, R. Paus (Hrsg.): Checkliste für Dermatologie und Venerologie.
    Thieme Verlag, Stuttgart 2004Hertl M (Hrsg.).
    Autoimmune diseases of the skin.
    Springer-Verlag, Wien (2. und erweiterte Auflage), 2005
  • Hertl M, Zillikens D
    Bullöse Autoimmundermatosen. In: Kurzlehrbuch Dermatologie und Venerologie, Hengge U, Ruzicka T (Hrsg.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2005
  • Veldman C, Hertl M.
    Autoimmunity against desmogleins in pemphigus vulgaris. In: Molecular Autoimmunity, Zouali M (Hrsg.), Springer Science + Business Media, Inc., New York, 2005